• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

CDKN2A antibody (pAb)

Host / Isotype

Rabbit / IgG

Reactivity

Human

Applications

IP, WB

Activ Motif logo

Cat No : 61619,61620 61619

Synonyms

CDKN2A, Cyclin-Dependent Kinase Inhibitor 2A, P16-INK4A, CDKN2, P16INK4, MTS1, P16INK4A, Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4), Multiple Tumor Suppressor 1, TP16, CDK4I, CDK4 Inhibitor P16-INK4, MTS-1, CMM2, P16, p16-INK4, ARF, p16-INK4a, INK4, p16INK4A, INK4A, tumor suppressor, dysplastic nevus syndrome, cdkn2a-related cutaneous malignant melanoma, transcript, antibody, antibodies, polyclonal, pab, western blotting, wb, immunoprecipitation, ip, samples

Validation Data Gallery

  • CDKN2A antibody (pAb) tested by Immunoprecipitation. 10 ul of CDKN2A antibody was used to immunoprecipitate CDKN2A from 400 ug of HeLa whole cell extract (lane 2). 10 ul of rabbit IgG was used as a negative control (lane 1). The immunoprecipitated protein was detected by Western blotting using the CDKN2A antibody at a dilution of 1:500.

    CDKN2A antibody (pAb) tested by Immunoprecipitation. 10 ul of CDKN2A antibody was used to immunoprecipitate CDKN2A from 400 ug of HeLa whole cell extract (lane 2). 10 ul of rabbit IgG was used as a negative control (lane 1). The immunoprecipitated protein was detected by Western blotting using the CDKN2A antibody at a dilution of 1:500.

  • CDKN2A antibody (pAb) tested by Western blot. Detection of CDKN2A by Western blot. The analysis was performed using 30 ug HeLa whole-cell extract and CDKN2A (pAb) at a 1:500 dilution.

    CDKN2A antibody (pAb) tested by Western blot. Detection of CDKN2A by Western blot. The analysis was performed using 30 ug HeLa whole-cell extract and CDKN2A (pAb) at a 1:500 dilution.

Product Information

Tested Applications IP, WB

Applications Validated by Active Motif: IP: 10 ul per IP WB: 1:500 - 1:2,000 dilution
Tested Reactivity Human
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen This antibody was raised against a peptide within the N-terminal region of the p16/INK4a isoform of human CDKN2A.
Full Name CDKN2A antibody (pAb)
Synonyms CDKN2A, Cyclin-Dependent Kinase Inhibitor 2A, P16-INK4A, CDKN2, P16INK4, MTS1, P16INK4A, Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4), Multiple Tumor Suppressor 1, TP16, CDK4I, CDK4 Inhibitor P16-INK4, MTS-1, CMM2, P16, p16-INK4, ARF, p16-INK4a, INK4, p16INK4A, INK4A, tumor suppressor, dysplastic nevus syndrome, cdkn2a-related cutaneous malignant melanoma, transcript, antibody, antibodies, polyclonal, pab, western blotting, wb, immunoprecipitation, ip, samples
Molecular weight 16 kDa
GenBank accession numberNP_000068
RRIDAB_2793705
Purification Method Affinity Purified
Buffer Purified IgG in PBS with 30% glycerol and 0.035% sodium azide. Sodium azide is highly toxic.
Storage Some products may be shipped at room temperature. This will not affect their stability or performance. Avoid repeated freeze/thaw cycles by aliquoting items into single-use fractions for storage at -20°C for up to 2 years. Keep all reagents on ice when not in storage.

Background Information

CDKN2A (Cyclin-Dependent Kinase Inhibitor 2A) is capable of inducing cell cycle arrest in G1 and G2 phases. Acts as a tumor suppressor. Binds to MDM2 and blocks its nucleocytoplasmic shuttling by sequestering it in the nucleolus. This inhibits the oncogenic action of MDM2 by blocking MDM2-induced degradation of p53 and enhancing p53-dependent transactivation and apoptosis. Also induces G2 arrest and apoptosis in a p53-independent manner by preventing the activation of cyclin B1/CDC2 complexes. Binds to BCL6 and down-regulates BCL6-induced transcriptional repression. Binds to E2F1 and MYC and blocks their transcriptional activator activity but has no effect on MYC transcriptional repression. Binds to TOP1/TOPOI and stimulates its activity. This complex binds to rRNA gene promoters and may play a role in rRNA transcription and/or maturation. Interacts with NPM1/B23 and promotes its polyubiquitination and degradation, thus inhibiting rRNA processing. Interacts with COMMD1 and promotes its 'Lys63'-linked polyubiquitination. Interacts with UBE2I/UBC9 and enhances sumoylation of a number of its binding partners including MDM2 and E2F1. Binds to HUWE1 and represses its ubiquitin ligase activity. May play a role in controlling cell proliferation and apoptosis during mammary gland development. Isoform 6 may be involved in regulation of autophagy and caspase-independent cell death; the short-lived mitochondrial isoform is stabilized by C1QBP. Multiple protein isoforms are encoded by this gene. The p16 isoform, also known as INK4a, is a CDK4 & CDK6 kinase inhibitor. It functions as negative regulator of the proliferation of normal cells and plays a role in aging and senescence.